CureVac 관리

관리 기준 확인 2/4

CureVac CEO는 Alexander Zehnder, Apr2023 에 임명되었습니다 의 임기는 1.58 년입니다. 총 연간 보상은 € 978.33K, 51.1% 로 구성됩니다. 51.1% 급여 및 48.9% 보너스(회사 주식 및 옵션 포함). 는 € 138.58K 가치에 해당하는 회사 주식의 0.025% 직접 소유합니다. 138.58K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 8.7 년입니다.

주요 정보

Alexander Zehnder

최고 경영자

€978.3k

총 보상

CEO 급여 비율	51.1%
CEO 임기	1.6yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Alexander Zehnder 의 보수는 CureVac 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€278m
Mar 31 2024	n/a	n/a	-€273m
Dec 31 2023	€978k	€500k	-€260m

보상 대 시장: Alexander 의 총 보상 ($USD 1.02M )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.03M ).

보상과 수익: Alexander 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Alexander Zehnder (54 yo)

1.6yrs

테뉴어

€978,331

보상

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alexander Zehnder	CEO, MD & Member of Management Board	1.6yrs	€978.33k	0.025% € 138.6k
Malte Greune	COO, Member of Management Board & MD	3.3yrs	€600.74k	0.0038% € 21.0k
Myriam Mendila	Chief Scientific Officer	1.8yrs	€614.49k	0.0021% € 11.7k
Ulrike Gnad-Vogt	Senior VP & Area Head of Oncology	1.8yrs	€284.15k	데이터 없음
Axel-Sven Malkomes	Chief Financial Officer	no data	데이터 없음	데이터 없음
Sarah Fakih	Vice President Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Marco Rau	General Counsel	no data	데이터 없음	데이터 없음
Thorsten Schuller	Head of Corporate Communications	no data	데이터 없음	데이터 없음
Slavica Stevanovic-Heck	Head of Human Resources	no data	데이터 없음	데이터 없음
Patrick Baumhof	Senior Vice President of Technology	no data	데이터 없음	데이터 없음
Ronald Plasterk	Senior Vice President of Science & Innovation	no data	데이터 없음	데이터 없음
Marcus Dalton	Head of Intellectual Property	no data	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: 5CV 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hans-Georg Rammensee	Scientific Director of Immunology and Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig Tooman	Supervisory Board Member	5.4yrs	€96.25k	0.0043% € 23.7k
Karim Fizazi	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Michael Brosnan	Independent Director of Supervisory Board	1.4yrs	€51.03k	0.0019% € 10.3k
Baron Stephenne	Independent Chairman of Supervisory Board	9.3yrs	€123.75k	0.0075% € 41.2k
Nina Bhardwaj	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Stanley Plotkin	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Michael Manns	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Jean-Paul Prieels	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Mathias Hothum	Supervisory Board Member	9.3yrs	€96.25k	0.0048% € 26.6k
Dirk Jäger	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음
Christopher Karp	Member of Scientific Advisory Board	8.7yrs	데이터 없음	데이터 없음

8.7yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 5CV 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.

CureVac 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024

CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. Announces Executive Changes

CureVac N.V., Annual General Meeting, Jun 19, 2023

Recent updates

Forecast to breakeven in 2024

CureVac N.V. to Report Q3, 2024 Results on Nov 12, 2024

Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024

CureVac N.V. to Present at the Society for Immunotherapy of Cancer 39th Annual Meeting

CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Second quarter 2024 earnings released: €0.32 loss per share (vs €0.30 loss in 2Q 2023)

CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024

CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €1.32 loss in FY 2022)

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.25 loss in 3Q 2022)

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: €0.30 loss per share (vs €0.31 loss in 2Q 2022)

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

CureVac N.V., Annual General Meeting, Jun 19, 2023

First quarter 2023 earnings released: €0.27 loss per share (vs €0.081 loss in 1Q 2022)

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Full year 2022 earnings released: €1.32 loss per share (vs €2.21 loss in FY 2021)

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

CureVac N.V. Announces CEO Changes

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

CureVac Announces Executive Changes

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.21 loss per share (vs €0.98 loss in FY 2020)

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2023

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021

CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV

CureVac N.V. Announces Results of the Second Interim Analysis of its International Pivotal Phase 2b/3 Study in Approximatively 40,000 Subjects

CureVac N.V.’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

CureVac N.V. Develops a New Class of Transformative Medicines Based on Messenger Ribonucleic Acid

Full year 2020 earnings released: €0.98 loss per share (vs €137 loss in FY 2019)

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

New 90-day low: €67.07

CureVac N.V. and UK Government to Collaborate on Development of Vaccines Against SARS-CoV-2 Variants

CureVac N.V. Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

GlaxoSmithKline plc and CureVac N.V. Announce New €150 Million Collaboration, Building on Their Existing Relationship, to Jointly Develop Next Generation mRNA Vaccines for COVID-19

CureVac and Rentschler Biopharma Ramp up for Joint Manufacturing of COVID-19 Vaccine, CVnCoV

CureVac N.V. Announces the Publication of Preclinical Data Demonstrating the Induction of Robust Antibody and T Cell Responses of its Covid-19 Vaccine Candidate

CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

Curevac N.V. Enrolls the First Participant in the Pivotal Phase 2b/3 Study of its mRNA Vaccine Candidate, CVnCoV, Against COVID-19

CEO 보상 분석

CEO